Biodesix, Inc.NASDAQ: BDSX

Biodesix to Participate in Upcoming Investor Conferences

· Issued by Biodesix, Inc. via GlobeNewswire

Summary by 6ix AI

Biodesix, Inc., a diagnostics company whose tests are used for patients with lung disease, said members of its leadership team will present at the UBS Global Healthcare Conference and the Craig-Hallum Alpha Select Conference.

Key details

  • UBS Global Healthcare Conference in Palm Beach Gardens, FL: a fireside chat (an informal question-and-answer session) on Tuesday, November 10 at 2:45 PM ET, plus one-on-one meetings.
  • Craig-Hallum Alpha Select Conference in New York, NY: one-on-one meetings only, on Tuesday, November 17.
  • The presentation will be webcast live, with a replay under News & Events in the Investors section of the Biodesix website.

6ix AI wrote this summary from the release below and checked it against the release.

LOUISVILLE, Colo., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present at two upcoming investor conferences:

UBS Global Healthcare Conference
Fireside chat and 1x1 meetings
Fireside Chat Date and Time: Tuesday, November 10, 2:45 PM ET
Location: Palm Beach Gardens, FL

Craig-Hallum Alpha Select Conference
1x1 meetings only
Date: Tuesday, November 17
Location: New York, NY

The presentation will be webcast live and available for replay under “News & Events” in the Investors section of Biodesix website at Biodesix.com.

About Biodesix:

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, including Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications
[email protected]
(720) 925-9285

Investors:
Chris Brinzey, Partner, ICR
[email protected]
(339) 970-2843

View original source (GlobeNewswire)Biodesix, Inc. on 6ix

Story so far

Earlier from Biodesix

Later from Biodesix

All Biodesix news releases